The final quarter of the year brought a wave of FDA activity that will meaningfully impact community pharmacies. From changes to biosimilar policy to new drug approvals and compounding oversight, Q4 underscored how quickly the regulatory landscape is evolving.
This recap highlights many significant FDA updates from October through December 2025 and what they mean for pharmacies in 2026.
Biosimilars shift the ground beneath dispensing practices
In November 2025, the FDA announced a change in how biosimilars can demonstrate interchangeability. Instead of requiring routine switching studies and comparative clinical trials, the agency signaled that advanced analytical data could be sufficient in many cases. This streamlined approach is likely to reduce development costs and accelerate biosimilar availability.
For independent pharmacies, this could translate into more options on the shelf, greater payer pressure to use biosimilars, and more frequent substitution decisions at the counter. Pharmacies will need to stay closely aligned with the FDA’s biosimilar guidance, state substitution laws, payer policies, and evolving formulary expectations.
Growing concern over compounded products
In December, heightened attention on compounded versions of high-demand therapies—especially compounded GLP-1 products—prompted renewed scrutiny across the industry. As stakeholders raised concerns about patient safety and product consistency, the FDA reiterated expectations for compounding under the Drug Quality and Security Act, including compliance with 503A/503B standards. For community pharmacies, this elevates the importance of rigorous documentation, ingredient sourcing and traceability, and clear patient education when a compounded product is used in place of an FDA-approved medication.
A milestone antibiotic NDA acceptance
Late in the quarter, the FDA accepted the New Drug Application (NDA) and granted Fast Track designation to Zaynich, an antibiotic developed by Wockhardt Ltd. This marked a historic moment as the first NDA acceptance of its kind from an Indian pharmaceutical manufacturer. While availability timelines may vary, community pharmacies should begin considering how this product might fit into existing antibiotic workflows, inventory management, and stewardship practices once it reaches the market.
A busy end-of-year regulatory calendar
December brought a flurry of FDA activity, with numerous advisory committee meetings and regulatory decisions across rare diseases, chronic conditions, and innovative therapies. The overall theme was clear: the FDA continues to balance rapid access to new treatments with careful attention to safety, labeling, and post-market monitoring.
For pharmacies, this means staying alert to late-breaking label updates, REMS requirements, and prescribing trends that could impact dispensing this year.
Debate continues around biosimilar substitution
Even with the FDA’s new analytical framework, questions about interchangeability and substitution remain unsettled at the state level. Laws differ widely, and payers continue to refine their preferences. Pharmacy owners and managers should maintain active relationships with their state boards of pharmacy and major insurers to ensure compliance and optimize reimbursement.
New novel drugs close out the year
The FDA approved several notable therapies in December, including:
- Tradipitant (brand name Nereus) for motion-related vomiting
- Narsoplimab-wuug (brand name Yartemlea) for transplant-associated complications
- Ficamten (brand name Myqorzo) for obstructive hypertrophic cardiomyopathy.
Each new approval brings practical considerations for community pharmacies, from updating NDC databases and pricing systems to preparing counseling points and workflow adjustments.
New FDA guidance affecting everyday practice
The agency also finalized key guidance documents in December related to advertising and promotion of biologics and biosimilars, as well as formal dispute resolution under the FD&C Act. These updates clarify how manufacturers can communicate about their products, but they also shape the information that ultimately reaches pharmacy teams and patients.
Looking ahead
As last quarter ended, several trends became clear: biosimilars will play a larger role, novel therapies will continue to enter the market, and regulatory scrutiny around compounding and promotion will persist. At the same time, reimbursement pressures from PBMs and evolving state laws will keep financial sustainability top of mind for independent pharmacies.
Pharmacies that stay informed, adapt their workflows, and proactively educate patients will be best positioned to thrive in this ever-changing landscape.
Want more resources for clinical and operational insights?
Join our email list for how-to guides, toolkits with ready-made marketing materials, and newsletters full of more blogs like these.
ABOUT THE AUTHOR
Michelle Barney, PharmD
Clinical Solutions Manager, Lumistry
Michelle Barney is a Clinical Solutions Manager at Lumistry, where she brings the practicing pharmacist’s perspective into the creation and evolution of pharmacy technology solutions. A clinical pharmacist by training, Michelle has built her career across retail pharmacy and health technology, including serving as Vice President of Clinical Operations at VUCA Health prior to its acquisition by Lumistry. She has held leadership roles spanning clinical operations, product, and marketing, and brings firsthand experience managing pharmacy teams and workflows. In her current role, Michelle partners closely with cross-functional teams to ensure Lumistry’s products are rooted in real-world pharmacy needs—helping pharmacies work more efficiently, confidently, and effectively in their day-to-day practice.
